文献速递腹部MR

钆塞酸二钠增强肝脏MRI双门静脉期对肝细胞癌无创诊断的个体内比较

Intra-individual comparison of dual portal venous phases for non-invasive diagnosis of hepatocellular carcinoma at gadoxetic acid-enhanced liver MRI.
PubMed 文献 · Eur Radiol · 2020-08-26

回顾性纳入123例高危患者160个肝脏病灶,在钆塞酸二钠增强MRI上比较第一门静脉期(PVP1,约53秒)与第二门静脉期(PVP2,约73秒)显示廓清和包膜征象对无创诊断HCC的效能。PVP2较PVP1检出更多廓清和强化包膜,按LI-RADS v2018或EASL标准敏感度和准确率更高,特异度无显著损失。

要点

  • PVP2较PVP1检出更多HCC廓清(83.6%对50.9%)和强化包膜(27.6%对19.8%)。
  • PVP2较PVP1敏感度更高:LI-RADS 83.6%对53.5%,EASL 82.8%对50.0%。
  • PVP2较PVP1准确率更高:LI-RADS 0.88对0.73,EASL 0.88对0.72。

关键影像表现/征象

  • HCC中PVP2观察到廓清83.6%、强化包膜27.6%,PVP1分别为50.9%和19.8%(p均<0.001)。
  • PVP2图像上更多HCC被归为LR-5,PVP2特异度93.5%与PVP1的93.5%相当。

诊断标准与关键数值

  • 按LI-RADS标准,PVP2敏感度83.6% vs PVP1 53.5%(p<0.001),准确率0.88 vs 0.73(p<0.001)。
  • 按EASL标准,PVP2敏感度82.8% vs PVP1 50.0%(p<0.001),准确率0.88 vs 0.72(p<0.001)。
  • 特异度PVP2 93.2% vs PVP1 93.2%(LI-RADS或EASL标准,p=0.32)。

临床应用与阅片要点

  • 阅片时关注门静脉期约70秒采集的图像,有助于更敏感地显示HCC廓清和强化包膜。
  • 两种PVP图像集均未将非HCC恶性肿瘤无创诊断为HCC。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To compare the diagnostic performances of first and second portal venous phases (PVP1 and PVP2) in revealing washout and capsule appearance for non-invasive HCC diagnoses in gadoxetic acid-enhanced MRI (Gd-EOB-MRI).

METHODS: This retrospective study included 123 at-risk patients with 160 hepatic observations (HCCs, n = 116; non-HCC malignancies, n = 18; benign, n = 26) showing arterial phase hyper-enhancement (APHE) ≥ 1 cm at Gd-EOB-MRI. The mean time intervals from gadoxetic acid injection to PVP1 and PVP2 acquisitions were 53 ± 2 s and 73 ± 3 s, respectively. After evaluating image findings independently, imaging findings and diagnoses were finalized by a consensus of two radiologists using either PVP1 or PVP2 image sets according to the LI-RADS v2018 or EASL criteria. Sensitivity, specificity, and accuracy were compared.

RESULTS: Among HCCs, more washout and enhancing capsule were observed in PVP2 (83.6% and 27.6%) than in PVP1 (50.9% and 19.8%) (p < 0.001, both). The PVP2 set presented significantly higher sensitivity (83.6% vs. 53.5%, LI-RADS; 82.8% vs. 50.0%, EASL; p < 0.001, both) and accuracy (0.88 vs. 0.73, LI-RADS; 0.88 vs. 0.72, EASL; p < 0.001, both) than the PVP1 set without significant specificity loss (93.2% vs. 93.2%, by LI-RADS or EASL; p = 0.32, both). None of the non-HCC malignancy was non-invasively diagnosed as HCC in both PVP image sets.

CONCLUSION: Late acquisition of PVP detected washout and enhancing capsule of HCC more sensitively than early acquisition, enabling accurate diagnoses of HCC, according to LI-RADS or EASL criteria.

KEY POINTS: • Among HCCs, more washout and enhancing capsules were observed in PVP2 than PVP1, quantitatively and qualitatively. • The portal venous phase acquired at around 70 s after contrast media administration (PVP2) provided significantly higher sensitivity and AUC value than PVP1 by using LI-RADS v2018 or EASL criteria. • More HCCs were categorized as LR-5 in PVP2 than in PVP1 images, and the specificity of PVP2 (93.5%) was comparable with PVP1 (93.5%).

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kang HJ, Lee JM, Jeon SK, et al. Intra-individual comparison of dual portal venous phases for non-invasive diagnosis of hepatocellular carcinoma at gadoxetic acid-enhanced liver MRI. Eur Radiol. 2020. PMID: 32845387. doi:10.1007/s00330-020-07162-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。